However, the “other side” of this type of expectable toxicity, referred to “on-target (targeting the CD19 antigen), off-tumour toxicity” associated to CAR-T cell is that as long as hypogammaglobulinemia persists, risk of infections increases as well [32]. Here, CD19 is linked to neoplasm.